Patients with type 2 diabetes mellitus (T2DM) face a naturally elevated risk of developing colorectal cancer, but new evidence suggests that a specific combination of medications may offer a significant protective effect. A recent study indicates that dual therapy using both SGLT-2 inhibitors and GLP-1 receptor agonists is associated with a lower risk of colon cancer compared to using SGLT-2 inhibitors alone.
The Impact of Dual Therapy on Colon Cancer Risk
Using a target trial emulation of data from the TriNetX Global Collaborative Network spanning 2017 to 2025, researchers examined adults with T2DM who had a history of polypectomy. The study compared patients receiving dual therapy—an SGLT-2 inhibitor combined with a GLP-1 receptor agonist—against those receiving SGLT-2 inhibitor monotherapy.
The results showed a 21% relative risk reduction in the incidence of colon cancer for those on dual therapy (HR 0.786, 95% CI 0.671–0.919; P = 0.003). The research as well noted significant reductions in the need for colectomies among the dual-therapy group.
SGLT-2 inhibitors and GLP-1 receptor agonists are classes of medications used to manage type 2 diabetes. Whereas their primary role is glucose control, research suggests they may possess anticancer properties through distinct biological mechanisms.
Broader Protective Trends and Comparisons
This finding aligns with a broader body of research suggesting that GLP-1 receptor agonists (GLP-1RAs) may generally lower the risk of colorectal cancer in patients with T2DM. Observational studies have highlighted this protective association, and some data suggests the effect may be more pronounced than other common preventative measures.
Research presented at the ASCO Gastrointestinal Cancers Symposium 2026 compared GLP-1RA users to aspirin users. The analysis found that the incidence of colorectal cancer among GLP-1RA users was approximately 36% lower than among those using aspirin (HR 0.643), with an even greater reduction seen in patients categorized as high risk (HR 0.579). These protective effects were observed regardless of whether the patients had diabetes.
These trends suggest that for many patients, these medications provide benefits that extend beyond blood sugar regulation.
The Semaglutide Exception
While the overall class trends appear protective, a network meta-analysis (NMA) of 68 randomized controlled trials involving 207,200 participants introduced a critical nuance. This analysis found that not all GLP-1 receptor agonists carry the same safety profile regarding colorectal tumors.

The NMA identified that only semaglutide was associated with an increased incidence of colorectal tumors compared to control groups. Specifically, a dose-stratified analysis revealed that high-dose injectable semaglutide (2.4 mg/week) was the only regimen linked to this increased risk. This association remained present even when the analysis focused exclusively on obese subjects.
Other GLP-1 receptor agonists and SGLT2 inhibitors did not demonstrate a significant association with the development of colorectal tumors in this specific analysis.
Clinical Implications and Uncertainty
The contradiction between broad observational data showing protection and specific trial data showing risk for high-dose semaglutide highlights the complexity of these therapies. For clinicians and patients, this means the choice of medication and the specific dosage may influence the long-term oncological risk profile.
Because these findings stem from different types of research—ranging from target trial emulations and observational studies to network meta-analyses—prospective validation remains necessary to confirm these associations and establish definitive safety guidelines.
How should these conflicting findings on specific drug dosages influence the way patients and doctors discuss long-term cancer screening?





